Protara Therapeutics, Inc. (TARA) Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs

Protara Therapeutics, Inc. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs

Protara Therapeutics, Inc. (TARA) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $9.61 million as of 2023-12-31, per its 10-K filed 2024-03-13.

Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross

us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2024-03-13

• 2023-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $9.61M.
• 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $3.42M.
• 2022-09-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $829.00K.
• 2021-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $437.00K.